Augurix raises CHF 3 million

The successful financing of CHF 3 million was fully subscribed by new private investors. The company will call on these funds in two tranches according to its financial requirements. The new funds, along with existing cash resources, will enable Augurix to expand the marketing of its products, and further advance its clinical and pre-clinical medical diagnostic devices pipeline. These resources will mainly support the regulatory submission in the USA of Simtomax, a rapid test for the early screening of Celiac Disease, and support the development of a program aiming at developing a new oral contrast agent dedicated to the early stratification of patients suffering from pre-fibrotic Inflammatory Bowel Diseases (IBD).

Augurix SA is a Swiss-based company active in the development and marketing of in-vitro medical diagnostics devices devoted to gastroenterology. Through its portfolio of products, Augurix addresses the medical need of early discrimination between organic and systemic gastrointestinal diseases. Augurix is commercializing a rapid in-vitro diagnostic test for the early discrimination of Celiac Disease, marketed under the brand Simtomax. Augurix is also developing innovative solutions dedicated to the diagnosis of patients suffering from IBD and other gastro-intestinal diseases. Augurix was founded in 2007 and has established offices and laboratory premises in Monthey (Valais, Switzerland).